Becotatug Vedotin (recombinant humanized anti-EGFR mAb-MMAE conjugate) combined with Pucotenlimab (recombinant humanized anti-PD-1 mAb)
Sponsors
Fudan University, Cancer Hospital Chinese Academy of Medical Science, Shenzhen Center
Conditions
HNPCCPenile Cancer
Phase 2
A Study of Becotatug Vedotin Combined With Pucotenlimab in the Treatment of EGFR-Positive Advanced Penile Cancer
RecruitingNCT07497919
Start: 2026-09-01End: 2029-05-01Target: 20Updated: 2026-09-18
A Prospective, Single-arm, Phase II Clinical Trial of Becotatug Vedotin for Injection Combined With Pucotenlimab Injection as a First-line Treatment for Platinum-intolerant Advanced Head and Neck Squamous Cell Carcinoma
Not yet recruitingNCT07628855
Start: 2026-05-14End: 2028-08-30Target: 30Updated: 2026-06-05